Slower-than-expected Hulio uptake in U.S.
Adalimumab biosimilar uptake has been gradual across the industry; Biocon's Hulio launched July 1, 2023, and payer decisions are still evolving, with meaningful revenue expected only by 2025.
BIOCON / Q1-FY24 / risks
Keep the risk register visible.
Biocon · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Regulatory delays for insulin aspart and bevacizumab approvals
USFDA inspections at Malaysia facility resulted in observations; CAPA plans submitted but approval timelines for insulin aspart and bevacizumab remain uncertain.
High debt and interest burden from Viatris acquisition
Net debt for Biocon Biologics is over $1.4 billion; depreciation, amortization, and interest increased by INR 353 crore YoY, pressuring net profit.
Pricing pressure and rebate volatility in U.S. biosimilars
Legacy rebate contracts caused a $15 million one-off impact on pegfilgrastim; pricing dynamics vary by product and channel, and further rebate adjustments could affect margins.